179 related articles for article (PubMed ID: 38244582)
1. Identification and validation of methylation-CpG prognostic signature for prognosis of hepatocellular carcinoma.
He C; Guo Z; Zhang H; Yang G; Gao J; Mo Z
Aging (Albany NY); 2024 Jan; 16(2):1733-1749. PubMed ID: 38244582
[TBL] [Abstract][Full Text] [Related]
2. Identification and characterization of a 25-lncRNA prognostic signature for early recurrence in hepatocellular carcinoma.
Fu Y; Wei X; Han Q; Le J; Ma Y; Lin X; Xu Y; Liu N; Wang X; Kong X; Gu J; Tong Y; Wu H
BMC Cancer; 2021 Oct; 21(1):1165. PubMed ID: 34717566
[TBL] [Abstract][Full Text] [Related]
3. Characterizing the key genes of COVID-19 that regulate tumor immune microenvironment and prognosis in hepatocellular carcinoma.
Gao S; Zhang L; Wang H
Funct Integr Genomics; 2023 Aug; 23(3):262. PubMed ID: 37540264
[TBL] [Abstract][Full Text] [Related]
4. Immunological Significance of Prognostic DNA Methylation Sites in Hepatocellular Carcinoma.
Xu Q; Hu Y; Chen S; Zhu Y; Li S; Shen F; Guo Y; Sun T; Chen X; Jiang J; Huang W
Front Mol Biosci; 2021; 8():683240. PubMed ID: 34124163
[No Abstract] [Full Text] [Related]
5. Identification of an Oxidative Stress-Related LncRNA Signature for Predicting Prognosis and Chemotherapy in Patients With Hepatocellular Carcinoma.
Zhong Z; Xu M; Tan J
Pathol Oncol Res; 2022; 28():1610670. PubMed ID: 36277962
[No Abstract] [Full Text] [Related]
6. Upregulated CANT1 is correlated with poor prognosis in hepatocellular carcinoma.
Liu T; Li ZZ; Sun L; Yang K; Chen JM; Han XY; Qi LM; Zhou XG; Wang P
BMC Cancer; 2023 Oct; 23(1):1007. PubMed ID: 37858061
[TBL] [Abstract][Full Text] [Related]
7. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.
Qu X; Zhao X; Lin K; Wang N; Li X; Li S; Zhang L; Shi Y
Front Immunol; 2022; 13():994019. PubMed ID: 36177006
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation biomarkers for diagnosis of primary liver cancer and distinguishing hepatocellular carcinoma from intrahepatic cholangiocarcinoma.
Bai Y; Tong W; Xie F; Zhu L; Wu H; Shi R; Wang L; Yang L; Liu Z; Miao F; Zhao Q; Zhang Y
Aging (Albany NY); 2021 Jul; 13(13):17592-17606. PubMed ID: 34237708
[TBL] [Abstract][Full Text] [Related]
9. Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma.
Li D; Shi Z; Liu X; Jin S; Chen P; Zhang Y; Chen G; Fan X; Yang J; Lin H
Hepatol Int; 2023 Feb; 17(1):112-130. PubMed ID: 36598701
[TBL] [Abstract][Full Text] [Related]
10. A novel five-gene signature predicts overall survival of patients with hepatocellular carcinoma.
Wang Z; Pan L; Guo D; Luo X; Tang J; Yang W; Zhang Y; Luo A; Gu Y; Pan Y
Cancer Med; 2021 Jun; 10(11):3808-3821. PubMed ID: 33934539
[TBL] [Abstract][Full Text] [Related]
11. A comprehensive study based on exosome-related immunosuppression genes and tumor microenvironment in hepatocellular carcinoma.
Yang Z; Li X; Pan C; Li Y; Lin L; Jin Y; Zheng J; Yu Z
BMC Cancer; 2022 Dec; 22(1):1344. PubMed ID: 36550445
[TBL] [Abstract][Full Text] [Related]
12. The significance of m6A RNA methylation regulators in predicting the prognosis and clinical course of HBV-related hepatocellular carcinoma.
Fang Q; Chen H
Mol Med; 2020 Jun; 26(1):60. PubMed ID: 32552682
[TBL] [Abstract][Full Text] [Related]
13. Integrative analysis of DNA methylation and gene expression identify a six epigenetic driver signature for predicting prognosis in hepatocellular carcinoma.
Li GX; Ding ZY; Wang YW; Liu TT; Chen WX; Wu JJ; Xu WQ; Zhu P; Zhang BX
J Cell Physiol; 2019 Jul; 234(7):11942-11950. PubMed ID: 30536816
[TBL] [Abstract][Full Text] [Related]
14. Identification and Validation of a Novel Six-Gene Expression Signature for Predicting Hepatocellular Carcinoma Prognosis.
Yan Z; He M; He L; Wei L; Zhang Y
Front Immunol; 2021; 12():723271. PubMed ID: 34925311
[TBL] [Abstract][Full Text] [Related]
15. DNA damage repair-related gene signature for identifying the immune status and predicting the prognosis of hepatocellular carcinoma.
Lu Y; Wang S; Chi T; Zhao Y; Guo H; Wang H; Feng L
Sci Rep; 2023 Nov; 13(1):18978. PubMed ID: 37923899
[TBL] [Abstract][Full Text] [Related]
16. Development and validation of a novel prognostic signature based on m6A/m5C/m1A-related genes in hepatocellular carcinoma.
Xiao Y; Li J; Wu J
BMC Med Genomics; 2023 Jul; 16(1):177. PubMed ID: 37525171
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Role of DNA Methylation Located in Cuproptosis-Related Genes: Implications for Prognosis and Immune Landscape in Hepatocellular Carcinoma.
Zhu R; Wang X; Sun F; Zhu L; Guo W
Front Biosci (Landmark Ed); 2024 Mar; 29(3):123. PubMed ID: 38538282
[TBL] [Abstract][Full Text] [Related]
18. Identification of molecular subtypes based on PANoptosis-related genes and construction of a signature for predicting the prognosis and response to immunotherapy response in hepatocellular carcinoma.
Zhu J; Huang Q; Peng X; Luo C; Liu Z; Liu D; Yuan H; Yuan R; Cheng X
Front Immunol; 2023; 14():1218661. PubMed ID: 37662906
[TBL] [Abstract][Full Text] [Related]
19. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
Luo Y; Liu H; Fu H; Ding GS; Teng F
Front Immunol; 2022; 13():974377. PubMed ID: 36458010
[TBL] [Abstract][Full Text] [Related]
20. A Novel Epigenetic Machine Learning Model to Define Risk of Progression for Hepatocellular Carcinoma Patients.
Bedon L; Dal Bo M; Mossenta M; Busato D; Toffoli G; Polano M
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33499054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
